Calendar of CURE/Yale BioHaven seminars for Fall 2010 now available. more
9/14
8:45 am - 6:00 pm
Ubifrance, the French Agency for international business development, cordially invites CURE members to this year's second French Biotech Tour, which aims to connect French and American Biotech companies specialized in neuroscience, inflammation, and auto-immune diseases. Philadelphia, PA. more
9/16
6:00 pm - 7:30 pm
CURE/Yale BioHaven presents Al Mann: 'Creating a successful medical device enterprise.' Hope Auditorium, Yale University, 315 Cedar Street, New Haven. more
10/5
Deadline for nominations for the Lemelson-MIT prize, awarded to an outstanding mid-career inventor who has developed a patented product or process of significant value to society. more
10/27
4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Cobalt Therapeutics. Anlyan Center, Yale University, 300 Cedar Street, New Haven. more
11/18
4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Biodel Inc. Anlyan Center, Yale University, 300 Cedar Street, New Haven. more
12/7
5:30 pm - 7:30 pm
CURE Holiday Party. Café George, 300 George Street, New Haven. Watch for details.


Cara Therapeutics, Inc.
 1 Parrot Drive
Shelton, CT 06484

Phone: 203 567 1500
Fax: 203 567 1510
Website: http://www.caratherapeutics.com

Contact(s)
Derek Chalmers - dchalmers@caratherapeutics.com

General Information

Cara Therapeutics is a clinical stage biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara’s pipeline includes drug candidates within several classes of peripherally-acting analgesics, along with a proprietary technology, GPCR DimerScreen™, for the discovery of innovative pain treatments based on novel pharmacological mechanisms

The Company’s lead drug development program encompasses peripherally-selective compounds that specifically activate kappa opioid receptors present on peripheral, pain-sensing nerves. Based on clinical studies conducted to date, and unlike currently marketed opioid receptor agonists, these new compounds have not demonstrated typical opiate side effects such as inhibition of intestinal transit (ileus), induction of life-threatening respiratory depression, or production of CNS side effects associated with euphoria or addiction.

Other Information
Ownership: Private
Parent Company: 35
World Employees: 35

Back

Designed by BlausenLisi
Copyright © 2006 Connecticut United for Research Excellence, Inc.